Abstract
Anguidine, a phase II agent, was used to treat 276 patients with solid tumors. The overall evaluability rate was 68%. Hematologic toxicity was substantial but not prohibitive. There were no complete responses, two partial responses, and 12 stabilizations.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Breast Neoplasms / drug therapy
-
Drug Evaluation
-
Head and Neck Neoplasms / drug therapy
-
Hematologic Diseases / chemically induced
-
Humans
-
Kidney Neoplasms / drug therapy
-
Leukocyte Count
-
Lung Neoplasms / drug therapy
-
Melanoma / drug therapy
-
Platelet Count
-
Sesquiterpenes / therapeutic use*
-
Trichothecenes / adverse effects
-
Trichothecenes / therapeutic use*
Substances
-
Sesquiterpenes
-
Trichothecenes
-
diacetoxyscirpenol